Exane Derivatives adds Catalent Inc (CTLT) to its portfolio

Catalent Inc (CTLT) : Exane Derivatives added new position in Catalent Inc during the most recent quarter end. The investment management firm now holds 55,161 shares of Catalent Inc which is valued at $1,396,677 , the company said in a statement filed on Aug 3, 2016 with the SEC.Catalent Inc makes up approximately 0.23% of Exane Derivatives’s portfolio.

Other Hedge Funds, Including , Sg Americas Securities boosted its stake in CTLT in the latest quarter, The investment management firm added 862 additional shares and now holds a total of 25,322 shares of Catalent Inc which is valued at $641,153.Oregon Public Employees Retirement Fund boosted its stake in CTLT in the latest quarter, The investment management firm added 4,647 additional shares and now holds a total of 36,520 shares of Catalent Inc which is valued at $924,686. Catalent Inc makes up approx 0.02% of Oregon Public Employees Retirement Fund’s portfolio.Acadian Asset Management boosted its stake in CTLT in the latest quarter, The investment management firm added 316,252 additional shares and now holds a total of 316,927 shares of Catalent Inc which is valued at $7,793,235. Catalent Inc makes up approx 0.04% of Acadian Asset Management’s portfolio.

Catalent Inc closed down -0.2 points or -0.79% at $25.13 with 4,48,589 shares getting traded on Monday. Post opening the session at $25.41, the shares hit an intraday low of $24.97 and an intraday high of $25.46 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Catalent Inc reported $0.20 EPS for the quarter, missing the analyst consensus estimate by $ -0.11 based on the information available during the earnings call on May 4, 2016. Analyst had a consensus of $0.31. The company had revenue of $438.00 million for the quarter, compared to analysts expectations of $427.05 million. The company’s revenue was down -1.9 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.46 EPS.

Many Wall Street Analysts have commented on Catalent Inc. Catalent Inc was Upgraded by Wells Fargo to ” Outperform” on Jun 21, 2016. Catalent Inc was Upgraded by BofA/Merrill to ” Buy” on Jun 20, 2016.

Catalent Inc. is a provider of advanced delivery technologies and development solutions for drugs biologics and consumer health products. The Company’s segments include Oral Technologies Medication Delivery Solutions and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies including formulation development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle. The Medication Delivery Solutions segment provides formulation development and manufacturing services for delivery of drugs and biologics administered through injection inhalation and ophthalmic routes using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing packaging storage and inventory management for drugs and biologics in clinical trials.

Leave a Reply

Catalent Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Catalent Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.